Autopsy report · NCT04791514

A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)

“Low enrolment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year 1 month before it started.
• Ran for about 5 months before it stopped.
• 1 participant enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Insmed Incorporated

Sponsor type

Industry

Conditions

Pulmonary Arterial Hypertension

Interventions

Treprostinil Palmitil

Participants

1

Sites

1

Countries

United States

Trials that died the same way

• Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan
  “Poor enrolment” (88% match in meaning)
• Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer
  “Low enrolment rate” (87% match in meaning)
• Trial of Caffeine to Alleviate Dyspnea Related to Ticagrelor
  “Too low enrolment rate” (84% match in meaning)
• FFP Versus PCC in Intracranial Hemorrhage
  “Lack of enrolment” (78% match in meaning)
• Efficacy Study of Pudendal Neuromodulation for the Treatment of Neurogenic Overactive Bladder
  “difficulty in the enrolment” (74% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.